Sonoma Pharmaceuticals (SNOA) Operating Expenses (2010 - 2026)

Sonoma Pharmaceuticals' Operating Expenses history runs 17 years deep, the most recent figure standing at $2.5 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 15.93% year-over-year to $2.5 million in Q1 2026; TTM through Mar 2026 was $9.9 million, a 7.64% increase from a year earlier, with the FY2026 full-year figure at $9.9 million, up 7.64% from the prior year.
• Operating Expenses rose to $2.5 million in Q1 2026 per SNOA's latest filing, from $2.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $3.2 million in Q1 2022 and bottomed at $2.0 million in Q1 2023.
• The 5-year median for Operating Expenses is $2.4 million (2023), against an average of $2.4 million.
• Across the five-year window, Operating Expenses sank 36.28% in 2023 and increased 24.32% in 2024, its largest moves.
• Year by year, Operating Expenses stood at $2.7 million in 2022, then fell by 13.55% to $2.3 million in 2023, then declined by 0.13% to $2.3 million in 2024, then increased by 1.17% to $2.3 million in 2025, then gained by 8.76% to $2.5 million in 2026.
• Per Business Quant, the three latest SNOA Operating Expenses figures stand at $2.5 million (Q1 2026), $2.3 million (Q4 2025), and $2.5 million (Q3 2025).